BioSpace News Archive

XORTX Therapeutics Inc. is pleased to announce positive topline results from its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2– (“Part 2”) showing a substantial increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with food compared to the fasted state.

WebPT, the leading rehab therapy platform for enhancing patient care and fueling business growth, today announces the release of the Keet Remote Therapeutic Monitoring (RTM) Dashboard and enhanced integrations with the WebPT and Insight EMRs.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) has transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb Corporation (“Bausch + Lomb”) to an existing wholly-owned unrestricted subsidiary of the Company (the “Internal Transfer”).

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31 st European Academy of Dermatology and Venereology (EADV) Congress.

Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31 st European Academy of Dermatology and Venerology Congress.

CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “ Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease ” in the American Journal of Preventive Cardiology.

Assure Holdings Corp. today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $6.2 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, received a $14.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI | OTCQX: VHIBF) is pleased to announce a licensing agreement of subsidiary Intouch with Health’s (“Intouch”) digital, at-home pre-op solutions, Synopsis Home and Synopsis iQ, to the Bolton NHS Foundation Trust (the “Trust” or “Bolton”).